FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

OCONNOR KEVIN 		2. Issuer Name and Ticker or Trading Symbol

ALBANY MOLECULAR RESEARCH INC [ AMRI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

26 CORPORATE CIRCLE 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/31/2017
(Street)

ALBANY, NY 12203
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/31/2017     D    58275   (1) D $21.75   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock   $13.54   8/31/2017     D         5000      (2) 6/11/2018   Common Stock   5000   $8.21   0   D    
Option to Purchase Common Stock   $9.19   8/31/2017     D         5000      (2) 11/20/2018   Common Stock   5000   $12.56   0   D    
Option to Purchase Common Stock   $8.81   8/31/2017     D         10000      (2) 6/3/2019   Common Stock   10000   $12.94   0   D    
Option to Purchase Common Stock   $6.15   8/31/2017     D         10000      (2) 6/2/2020   Common Stock   10000   $15.60   0   D    
Option to Purchase Common Stock   $5.28   8/31/2017     D         10000      (2) 6/8/2021   Common Stock   10000   $16.47   0   D    
Option to Purchase Common Stock   $2.59   8/31/2017     D         10000      (2) 6/13/2022   Common Stock   10000   $19.16   0   D    
Option to Purchase Common Stock   $5.99   8/31/2017     D         12367      (2) 1/31/2023   Common Stock   12367   $15.76   0   D    
Option to Purchase Common Stock   $10.43   8/31/2017     D         7201      (2) 2/4/2024   Common Stock   7201   $11.32   0   D    
Option to Purchase Common Stock   $17.05   8/31/2017     D         6881      (2) 3/2/2025   Common Stock   6881   $4.70   0   D    
Option to Purchase Common Stock   $15.77   8/31/2017     D         6540      (2) 2/4/2026   Common Stock   6540   $5.98   0   D    
Option to Purchase Common Stock   $18.41   8/31/2017     D         9358      (2) 2/8/2027   Common Stock   9358   $3.34   0   D    

Explanation of Responses:
(1)  Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
(2)  Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
OCONNOR KEVIN
26 CORPORATE CIRCLE
ALBANY, NY 12203 		X



Signatures
/s/ Lori M. Henderson, attorney-in-fact 9/5/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Albany Molecular Research, Inc. (NASDAQ:AMRI)
過去 株価チャート
から 10 2024 まで 11 2024 Albany Molecular Research, Inc.のチャートをもっと見るにはこちらをクリック
Albany Molecular Research, Inc. (NASDAQ:AMRI)
過去 株価チャート
から 11 2023 まで 11 2024 Albany Molecular Research, Inc.のチャートをもっと見るにはこちらをクリック